8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Nov 7, 2018)

Filed November 7, 2018For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on November 7, 2018, to report its financial results for the third quarter ended September 30, 2018. The filing itself is brief, primarily serving as a vehicle to furnish the accompanying press release (Exhibit 99.1), which contains the detailed financial and operational update. Investors should focus on the content of the press release for key performance indicators, revenue figures, pipeline updates, and forward-looking statements. This 8-K signifies the official release of this information to the public and the market. The filing also confirms the role of Manmeet S. Soni, Senior Vice President and Chief Financial Officer, in the company's financial reporting.

Key Highlights

  • 1Alnylam Pharmaceuticals reported its Q3 2018 financial results on November 7, 2018.
  • 2The 8-K filing primarily serves to furnish the press release containing the financial results.
  • 3The press release (Exhibit 99.1) is the key document for detailed financial and operational information.
  • 4The filing indicates no early adoption of new or revised financial accounting standards for emerging growth companies.
  • 5The Chief Financial Officer, Manmeet S. Soni, signed the filing.
  • 6Information furnished under Item 2.02 is not considered 'filed' for liability purposes under Section 18 of the Exchange Act.

Frequently Asked Questions

The detailed financial results for the third quarter ended September 30, 2018, are provided in the press release furnished as Exhibit 99.1 to this Form 8-K filing.

No, the information furnished under Item 2.02 of this Form 8-K, including the press release, is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, meaning it generally does not carry the same legal liability as officially filed documents.

In this filing, the check box being unchecked indicates that Alnylam has elected *not* to use the extended transition period for complying with new or revised financial accounting standards. This means they are adopting new accounting standards at the same time as other public companies.